Experimentación Animal, Unidad de Investigación Preclínica (UNIPREC), Facultad de Química, Universidad Nacional Autónoma de México, Mexico City, Ciudad de México, Mexico
+1
Prof. Joselo Ramon Martínez-Rosas
Experimentación Animal, Unidad de Investigación Preclínica (UNIPREC), Facultad de Química, Universidad Nacional Autónoma de México, Mexico City, Ciudad de México, Mexico
In this report, we investigated whether the use of chitosan-carrying-glutathione nanoparticles (CH-GSH NPs) can modify proliferation and apoptosis, and reduce cell damage induced by doxorubicin on breast cancer cells. Doxorubicin is a widely used antineoplasic agent for the treatment of various types of cancer. However, it is also a highly toxic drug because it induces oxidative stress. Thus, the use of antioxidant molecules has been considered to reduce the toxicity of doxorubicin. CH-GSH NPs were characterized in size, zeta potential, concentration, and shape. When breast cancer cells were treated with CH-GSH nanoparticles, they were localized in the cellular cytoplasm. Combined doxorubicin exposure with nanoparticles increased intracellular GSH levels. At the same time, decreasing levels of reactive oxygen species and malondialdehyde were observed and modified antioxidant enzyme activity. Levels of the Ki67 protein were evaluated as a marker of cell proliferation and the activity of the Casp-3 protein related to cell apoptosis was measured. Our data suggests that CH-GSH NPs can modify cell proliferation by decreasing Ki67 levels, induce apoptosis by increasing caspase-3 activity, and reduce the oxidative stress induced by doxorubicin in breast cancer cells by modulating molecules associated with the cellular redox state. CH-GSH NPs could be used to reduce the toxic effects of this antineoplastic. Considering these results, CH-GSH NPs represent a novel delivery system offering new opportunities in pharmacy, material science, and biomedicine.
Nanoparticles can modify the signaling pathways related to the toxic effects of xenobiotics and their toxicity by adding compounds that alter the oxidation–reduction state, such as glutathione (GSH). This work aimed to evaluate the antioxidant capacity of chitosan–glutathione nanoparticles (NPs Q‐GSH) to modify lipoperoxidation induced by sodium arsenate using a primary culture of rat chondrocytes as a model. NPs Q‐GSH were characterized in size (205.4 ± 33.35 nm), zeta potential (25.6 mV), and percentage of GSH (99.97%). To determine whether the toxicity of sodium arsenate was modified, chondrocytes were exposed to two concentrations of nanoparticles (0.08 and 0.64 μM GSH) for 2 h, followed by a 2‐h acute exposure to sodium arsenate at a concentration of 1 × 10−6 M, and the determinations associated with the redox state were carried out. ANOVA was performed, followed by multiple analyses of Fisher's means with a p < 0.05. Regarding the measurement of biomarkers, an increase in GSH levels was observed, which can be both synthesized by the cell and provided by the NPs Q‐GSH. A reduction in malondialdehyde levels was observed in the presence of an oxidizing agent, such as sodium arsenate, and subsequent exposure to NPs. Finally, the activity of the enzyme glutathione peroxidase increased significantly compared with untreated cells, which may be associated with GSH being its substrate and, therefore, favoring the activation of this enzyme. The activity of superoxide dismutase decreased, as did the levels of oxidized proteins. These systems could modify the signaling pathways associated with the redox state.
Background/Objectives: Resveratrol (RSV) is a phenolic compound that possesses antioxidant properties and whose biological application has been limited by its physicochemical properties, including its low solubility and stability. Methods: In this study, polymeric nanoparticles (NPs) were developed using polylactic acid (PLA) to encapsulate resveratrol and improve its bioavailability, using a factorial design to optimize the formulation and evaluate its cytotoxicity against breast cancer cells. Results: The optimized system presented an average size of 389.2 nm, a PDI of 0.127, a negative z-potential, and an encapsulation efficiency of 76.02%. The statistical analysis indicated that the PLA: RSV ratio was the main determinant of encapsulation percentage and particle size (p < 0.05). On the other hand, with the hemolysis test, blood compatibility was evidenced at all concentrations evaluated, while in the cell assays, the PLA-RSV nanoparticles significantly decreased the cellular viability of MCF-7 and MDA-MB 231 cells compared to untreated cells, and in combination with NP PLA-RSV and doxorubicin, greater cytotoxicity was produced in MCF-7 cells compared to nanoparticle-only treatments (p < 0.05, ANOVA, via followed by a Fisher test). Conclusions: In addition, distinct cytotoxic effects are observed, associated with their tumor phenotype. Taken together, these results suggest that PLA-RSV NPs are a useful system for future studies on redox status and other biological processes important in cancer.